BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » iPS Cells » Page 3

The State of iPS Cell Clinical Trials in 2021

By

Numerous induced pluripotent stem cell (iPSC) derived therapeutics are now being studied in preclinical and clinical trials to investigate their potential to produce functional cells capable of replacing damaged or dysfunctional tissues.

It is important to note that the early clinical trials of iPSCs—and the majority of them today—do not involve the transplant of iPSCs into humans. Rather, they involve the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest. [Read more…]

I Peace’s GMP-grade iPSCs are key to manufacture Avery Therapeutics’ MyCardia™, a proprietary tissue-engineered heart graft developed to treat heart failure

By

TUCSON, Ariz. and PALO ALTO, Calif., Dec. 16, 2020 — Avery Therapeutics, a Tucson-based company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, and I Peace, Inc., a Palo Alto-based biotech startup developing, mass-manufacturing, and commercializing Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs), announced a service agreement to advance cell therapy for heart failure. Under the agreement, I Peace will generate and supply GMP-grade induced pluripotent stem cells (iPSCs) and related services to Avery Therapeutics. Avery Therapeutics will use the iPSCs to derive cells used in the manufacturing of MyCardia™. [Read more…]

The French Blood Agency announces agreement with TreeFrog Therapeutics to scale-up manufacturing of iPS-derived hematopoietic stem cell transplants

By

TreeFrog Therapeutics will apply its proprietary technology for the mass-production of stem cell therapies to the world-first single-step protocol allowing the differentiation of human induced pluripotent stem cells (iPSCs) into fully functional human hematopoietic stem cells (HSCs). Resulting off-the-shelf universal HSC grafts could reduce costs and waiting times for patients in need of a bone marrow transplant.

Bordeaux, France – November, 17th, 2020 —The French Blood Agency (EFS) and TreeFrog Therapeutics announce a partnership to advance the mass-production of iPSC-derived HSC transplants based on a patented differentiation protocol developed by the EFS (UMR S938), the Institute for Radioprotection and Nuclear Safety (IRSN) and Sorbonne University[1]. [Read more…]

Do You Know The 5 Types Of Stem Cells?

By

As you start to learn about stem cells, one of the most common questions to have is, “What types of stem cells exist?” There is not an agreed-upon number of stem cell types, because one can classify stem cells either by differentiation potential (what they can turn into) or by origin (from where they are sourced). This post is dedicated to explaining the five types of stem cells, based on differentiation potential. [Read more…]

BioInformant's World-Class Clients